AI Article Synopsis

  • Sixty COVID-19 patients were divided into mild and severe groups to study their immune responses using flow cytometry and blood tests.
  • In the mild group, there was a notable increase in certain immune cell markers, indicating a stronger immune activation compared to the severe group, which exhibited lower CD4 cell counts but significant migration and proliferation of other lymphocytes.
  • The findings suggest that the mild cases might have better cellular immunity, which could imply that vaccination could help reduce the severity of COVID-19 and lower the risk of long-term complications.

Article Abstract

Sixty patients with COVID-19 infection were categorized into mild and severe groups, and their immune response was analyzed using flow cytometry and complete blood count. An observed increase in immune activation parameters, notably a higher percentage of CD4 lymphocytes co-expressing CD69 and CD25 molecules, and enhanced activity of the macrophage-monocyte cell line was noted in the mild group. Although Group 2 (severe COVID) had fewer CD4 cells, significant migration and proliferation were evident, with increased CD4CD69, CD8 HLA-DR+, and CD8CD69 lymphocytes. The CD4 to CD8 ratio in Group 1 suggested potential autoimmune reactions, while Group 2 indicated potential immunosuppression from severe infection and employing immunosuppressive drugs. Additionally, Group 2 exhibited an increased neutrophil count, hinting at possible bacterial co-infection. Group 1 showed differences in CD4RO and CD8RA lymphocyte populations, implying that cellular immunity plays a role in developing efficient postinfectious immunity. This intimation suggests that vaccination might mitigate the severity of the coronavirus infection and prevent complications, including long-term COVID-19.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10925834PMC
http://dx.doi.org/10.5339/qmj.2024.11DOI Listing

Publication Analysis

Top Keywords

immune response
8
mild severe
8
group
6
response variation
4
variation mild
4
severe
4
severe covid-19
4
covid-19 patients
4
patients sixty
4
sixty patients
4

Similar Publications

The anti-tumor effect of the IFNγ/Fas chimera expressed on CT26 tumor cells.

Anim Cells Syst (Seoul)

January 2025

Department of Biochemistry, College of Natural Sciences, Chungnam National University, Daejeon, Korea.

Interferon gamma (IFNγ) is well-known for its ability to stimulate immune cells in response to pathogen infections and cancer. To develop an effective cancer therapeutic vaccine, CT26 colon carcinoma cells were genetically modified to express IFNγ either as a secreted form (sIFNγ) or as a membrane-bound form. For the membrane-bound expression, IFNγ was fused with Fas (mbIFNγ/Fas), incorporating the extracellular cysteine-rich domains, transmembrane, and cytoplasmic domains of Fas.

View Article and Find Full Text PDF

Prognostic value and immune landscapes of disulfidptosis‑related lncRNAs in bladder cancer.

Mol Clin Oncol

February 2025

Department of Urology Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, P.R. China.

Disulfidptosis, which was recently identified, has shown promise as a potential cancer treatment. Nonetheless, the precise role of long non-coding RNAs (lncRNAs) in this phenomenon is currently unclear. To elucidate their significance in bladder cancer (BLCA), a signature of disulfidptosis-related lncRNAs (DRlncRNAs) was developed and their potential prognostic significance was explored.

View Article and Find Full Text PDF

A 47-year-old woman with a 12-year history of anemia and high C-reactive protein (CRP) levels was admitted to our hospital with worsening fatigue and night sweats. She had high levels of immunoglobulin G (IgG; 4182 mg/dL), IgA (630.6 mg/dL), and CRP (7.

View Article and Find Full Text PDF

Background: The systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) are novel inflammation-related markers calculated based on peripheral blood count. Data on biomarkers for the prognosis of peripheral artery disease (PAD) are limited. We aimed to evaluate the impact of these four inflammation-related biomarkers on mid-term restenosis and mortality rates in PAD patients.

View Article and Find Full Text PDF

EBV-specific T-cell immunity: relevance for multiple sclerosis.

Front Immunol

December 2024

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Genetic and environmental factors jointly determine the susceptibility to develop multiple sclerosis (MS). Improvements in the design of epidemiological studies have helped to identify consistent environmental risk associations such as the increased susceptibility for MS following Epstein-Barr virus (EBV) infection, while biological mechanisms that drive the association between EBV and MS remain incompletely understood. An increased and broadened repertoire of antibody and T-cell immune responses to EBV-encoded antigens, especially to the dominant CD4 T-cell EBV nuclear antigen 1 (EBNA1), is consistently observed in patients with MS, indicating that protective EBV-specific immune responses are deregulated in MS and potentially contribute to disease development.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!